Educational Modules

In this introductory module, participants will gain a clear understanding of the underlying mechanisms that drive hypertriglyceridemia. Learners will explore:

• How triglycerides are normally synthesized, transported, and metabolized in the body
• The role of lipoproteins, enzymes (e.g., LPL, ApoC-III), and hormonal regulation in triglyceride balance
• Genetic and acquired factors that lead to elevated triglycerides
• The pathophysiologic link between severe HTG and complications such as pancreatitis and increased cardiovascular risk

By the end of this module, participants will be able to explain the key pathways involved in triglyceride metabolism, recognize the mechanisms that contribute to dysregulation, and set the foundation for evaluating and treating patients with elevated triglycerides.

In Module #2, participants will gain a clear understanding of the clinical significance and management of chylomicronemia in the setting of severe hypertriglyceridemia. Learners will explore:

• The relationship between severe hypertriglyceridemia, chylomicronemia, and a markedly increased risk of acute pancreatitis
• The clinical presentation and pathophysiology of chylomicronemia, including the definitions of genetic FCS, clinical FCS, and persistent chylomicronemia
• Dietary and lifestyle counseling strategies and foundational pharmacotherapy for the management of chylomicronemia
• The role of newly approved apo C-III inhibitors as advanced therapy for the prevention of acute pancreatitis in chylomicronemia

By the end of this module, participants will be able to recognize high-risk chylomicronemia, differentiate emerging clinical phenotypes, implement evidence-based lifestyle and pharmacologic interventions, and determine when to escalate care with apoC-III inhibitors to reduce the risk of acute pancreatitis.

In Module #3, participants will gain a clear understanding of guideline-directed management of hypertriglyceridemia and its role in reducing atherosclerotic cardiovascular disease (ASCVD) risk and preventing pancreatitis. Learners will explore:

• The clinical implications of mild, moderate, and severe hypertriglyceridemia and their association with ASCVD and pancreatitis risk
• Physiologic, secondary, and medication-related causes of hypertriglyceridemia and their impact on patient management
• Evidence-based dietary, lifestyle, and behavioral interventions that form the foundation of triglyceride lowering
• Guideline-recommended pharmacologic strategies, including statin optimization, nonstatin therapies, and emerging treatments for patients with persistent hypertriglyceridemia

By the end of this module, participants will be able to apply the 2026 ACC/AHA dyslipidemia guidelines to stratify triglyceride-related risk, identify contributing factors, implement effective lifestyle and pharmacologic interventions, and tailor treatment strategies to reduce ASCVD risk and prevent triglyceride-related complications, including acute pancreatitis.

In Module #4, participants will gain an understanding of triglyceride (TG) biology, its role in cardiovascular and metabolic risk, and the evolving landscape of triglyceride-lowering therapies. Learners will explore:

• The spectrum of hypertriglyceridemia (mild to severe) and its association with cardiovascular disease, pancreatitis, and broader cardiometabolic complications
• Key features of triglyceride metabolism under physiologic and pathologic conditions, including the role of remnant lipoproteins and ApoC-III–mediated pathways
• Evidence from major clinical trials evaluating traditional TG-lowering therapies, highlighting their limitations in reducing cardiovascular outcomes despite lipid improvements
• Clinical trial data supporting newer therapeutic approaches, and their potential to address residual risk and prevent complications such as pancreatitis

By the end of this module, participants will be able to interpret clinical trial evidence for both legacy and novel TG-lowering therapies, apply a phenotype-driven approach to the management of hypertriglyceridemia, and integrate emerging treatment strategies to reduce cardiovascular risk and prevent triglyceride-related complications.